Document is current
Any future updates will be listed below
-
Authors
Geng, Xiaodong
Fu, Zhangning
Geng, Guangrui
Chi, Kun
Liu, Chao
Hong, Haijuan
Cai, Guangyan
Chen, Xiangmei
Hong, Quan
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82204744, 82270758, 82020741, 82200780)
China Postdoctoral Science Foundation (2022M723899)
Shanghai Songjiang District Scientific and Technological Project (2023SJKJGG054)
- License Information
-
More Information
Article History
Received: 26 July 2024
Accepted: 28 October 2024
First Online: 14 November 2024
Declarations
:
: All animal experiments were conducted in accordance with the ARRIVE guidelines 2.0 (Animal Research: Reporting of In Vivo Experiments) and approved by the by the Ethics Committee for the Use of Animals of PLA General Hospital. (Approval No. 2022-X18-36, “Astilbin improves the therapeutic effects of mesenchymal stem cells in AKI-CKD mice by regulating macrophage polarization through PTGS2-mediated pathway” approved on November 5, 2022). Human bone marrow MSCs were obtained from Cyagen Company (Guangzhou, China). Cyagen Company has confirmed that there was initial ethical approval for collection of human cells, and that the donors had signed informed consent.
: All authors confirm their consent for publication.
: The authors declare that they have no competing interests.
